Processa Pharmaceuticals
PCSA
11 hedge funds and large institutions have $75.9K invested in Processa Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
20% more capital invested
Capital invested by funds: $63.2K → $75.9K (+$12.7K)
3.88% less ownership
Funds ownership: 4.62% → 0.74% (-3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17.2K |
| 2 |
VF
Virtu Financial
New York
|
+$16.4K |
| 3 |
AGM
Alpine Global Management
New York
|
+$14.3K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$11.2K |
| 5 |
Jane Street
New York
|
+$5.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$20.7K |
| 2 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$3.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7 |
PCSA Hedge Fund Activity: Q2 2025 in Review
11 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2025, worth a combined $75.9K — up 20% from $63.2K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $17.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $20.7K sold.
- 11 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2025, up from 9 in Q1 2025.
- Funds reported $75.9K of Processa Pharmaceuticals stock for Q2 2025, up 20% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +2 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $17.2K added.
- The largest Processa Pharmaceuticals seller in Q2 2025 was Armistice Capital, an estimated $20.7K sold.
Based on aggregated 13F filings for Q2 2025.